202
Views
10
CrossRef citations to date
0
Altmetric
Letter to the editor

Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy

, , , &
Pages 2934-2936 | Received 13 Feb 2016, Accepted 04 Apr 2016, Published online: 27 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Laura Atzori, Caterina Ferreli & Franco Rongioletti. (2018) Advances in understanding and treatment of scleromyxedema. Expert Opinion on Orphan Drugs 6:5, pages 319-328.
Read now

Articles from other publishers (9)

Maria Caridad Duran-Lemarie, Luis Enrique Cano-Aguilar, Cristina Berumen-Glinz, Zonia Quijada-Ucelo, Heidi Hernandez-Ramirez, Mariana De Anda-Juárez & Elisa Vega-Memije. (2022) Combination of Medical and Surgical Treatment in Scleromyxedema. Cureus.
Crossref
Jochen H. O. Hoffmann & Alexander H. Enk. (2020) Skleromyxödem. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18:12, pages 1449-1468.
Crossref
Jochen H. O. Hoffmann & Alexander H. Enk. (2020) Scleromyxedema. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18:12, pages 1449-1467.
Crossref
Roger Haber, Julien Bachour & Maria El Gemayel. (2020) Scleromyxedema treatment: a systematic review and update. International Journal of Dermatology 59:10, pages 1191-1201.
Crossref
Á. Iglesias-Puzas & P. Boixeda. (2020) Deep Learning and Mathematical Models in Dermatology. Actas Dermo-Sifiliográficas (English Edition) 111:3, pages 192-195.
Crossref
Á. Iglesias-Puzas & P. Boixeda. (2020) Deep learning y DerMATología. Actas Dermo-Sifiliográficas 111:3, pages 192-195.
Crossref
Laura Atzori, Caterina Ferreli & Franco Rongioletti. (2019) New insights on scleromyxedema. Journal of Scleroderma and Related Disorders 4:2, pages 118-126.
Crossref
Chiedu E Ufodiama, Gregory Tynes & Rashmi Unwala. (2019) Clinical features of scleromyxoedema in an Afro-Caribbean man. BMJ Case Reports 12:1, pages e227588.
Crossref
. (2016) Dexamethasone/melphalan. Reactions Weekly 1629:1, pages 104-104.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.